FDA approves Vera Therapeutics’ Trutakna for autoimmune kidney disease IgA nephropathy
TL;DR
The FDA approved Vera Therapeutics' drug Trutakna to treat IgA nephropathy, a chronic autoimmune kidney disease that can progress to kidney failure, marking a milestone for Vera and advancing biotech options for patients.
- FDA approves Vera Therapeutics kidney disease treatment STAT
- US FDA approves Vera's kidney disease drug Reuters
- FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka Fierce Pharma
- Trutakna Approved to Reduce Proteinuria in Primary IgA Nephropathy Medical Professionals Reference
- 'I got back to living my normal life': How Vera Therapeutics' drug renewed a kidney patient ahead of FDA test The Business Journals
Want the full story? Read the original reporting
Read on STAT